Article Dans Une Revue ASAIO Journal Année : 2025

Apixaban Anticoagulation in HeartMate 3 Left Ventricular Assist Device

Résumé

BTT, bridge-to-transplant DOAC, direct oral anticoagulants DT, destination therapy HRAE, hemocompatibility-related adverse event HTx, heart transplantation LVAD, left ventricular assist device RCT, randomized controlled trial RR, relative risk VKA, vitamin K antagonist

Purpose of the study and main results

Although Vitamin-K antagonists (VKAs) are the gold-standard for anticoagulation in patients with left ventricular assist device (LVAD), apixaban has been suggested as a bleedingreducing alternative, but its use remains controversial. We performed a meta-analysis of randomised controlled trials (RCTs) assessing safety of apixaban in LVAD patients compared with VKAs. Seventy-five patients were randomized to apixaban (n = 47) or warfarin (n = 28).

Survival-free from hemocompatibility-related adverse events was similar between groups (RR 0.90 [0.77 -1.05], p = 0.55). No patients experienced thromboembolic complications.

Apixaban appears feasible in selected LVAD patients and large-scale RCTs are warranted to clarify its use.

Fichier sous embargo
Fichier sous embargo
Fichier sous embargo
0 5 24
Année Mois Jours
Avant la publication
lundi 28 juillet 2025
Fichier sous embargo
0 5 24
Année Mois Jours
Avant la publication
lundi 28 juillet 2025
Fichier sous embargo
lundi 28 juillet 2025
Connectez-vous pour demander l'accès au fichier

Dates et versions

hal-04922854 , version 1 (31-01-2025)

Identifiants

Citer

Miloud Cherbi, Christophe Vandenbriele, Guillaume Baudry, Clément Delmas. Apixaban Anticoagulation in HeartMate 3 Left Ventricular Assist Device. ASAIO Journal, 2025, ⟨10.1097/MAT.0000000000002385⟩. ⟨hal-04922854⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More